成人费城染色体阳性急性淋巴细胞白血病管理的当前范式
费城染色体阳性急性淋巴细胞白血病是前体B细胞急性淋巴细胞白血病的独特亚型,其发生率随年龄增长而升高,在60岁及以上患者中约占50%。传统化疗预后极差,尤其在未接受异基因造血细胞移植者中。随着多种酪氨酸激酶抑制剂的出现,治疗手段快速扩展,但尚无共识确定最佳治疗策略,本文结合现有文献讨论了相关争议。
要点
- 费城染色体阳性急性淋巴细胞白血病在60岁及以上患者中发生率约50%。
- 传统化疗预后极差,尤其未在首次完全缓解期接受异基因造血细胞移植者。
- 多种酪氨酸激酶抑制剂使治疗手段快速扩展,但最佳治疗策略尚无共识。
核心结论
- 费城染色体阳性急性淋巴细胞白血病的最佳治疗尚无共识,现代治疗改善预后后涌现出是否需要强化化疗、理想酪氨酸激酶抑制剂选择及是否所有合格患者应接受异基因造血细胞移植等争议。
研究设计与样本
- 本文为综述,基于现有文献讨论费城染色体阳性急性淋巴细胞白血病成人患者管理中的争议。
主要发现
- 费城染色体源于9号染色体ABL1激酶基因与22号染色体BCR基因的相互易位,通常产生p210 BCR-ABL1或p190 BCR-ABL癌蛋白,两者均为组成性活跃的酪氨酸激酶。
- 在费城染色体阳性急性淋巴细胞白血病中,p190-BCR-ABL(次要[m]-bcr)亚型比p210-BCR-ABL(主要[M]-bcr)亚型更常见,后者常见于慢性髓性白血病。
- 费城染色体是老年急性淋巴细胞白血病患者中最常见的复发性细胞遗传学异常,其发生率随年龄增长而升高,在60岁及以上患者中约占50%。
- 传统化疗下患者预后极差,尤其未在首次完全缓解期接受异基因造血细胞移植者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) is a biologically, clinically, and genetically distinct subtype of precursor-B ALL. The Ph chromosome, results from a reciprocal translocation of the ABL1 kinase gene on chromosome 9 to the breakpoint cluster region (BCR) gene on chromosome 22. Depending on the translocation breakpoint, typically a p210 BCR-ABL1 or a p190 BCR-ABL onc protein are generated; both are constitutively active tyrosine kinases that play a central role to alter signaling pathways of cell proliferation, survival, and self-renewal, leading to leukemogenesis. In Ph-positive ALL, the p190-BCR-ABL (minor [m]-bcr) subtype is more frequent than the p210-BCR-ABL (major [M]-bcr) subtype, commonly found in chronic myeloid leukemia. The Philadelphia chromosome is the most frequent recurrent cytogenetic abnormality in elderly patients with ALL. Its incidence increases with age, reaching ∼50% in patients with ALL aged 60 years and over. Patients traditionally had a very poor outcome with chemotherapy, particularly if they do not undergo allogeneic hematopoietic cell transplantation (allo-HCT) in first complete remission (CR1). With the availability of multiple tyrosine kinase inhibitors (TKI), the therapeutic armamentarium is expanding quickly. However, there is no consensus on how to best treat Ph-positive ALL. With modern therapy, improved outcomes have led to the emergence of a number of controversies, including the need for intensive chemotherapy, the ideal TKI, and whether all eligible patients should receive an allo-HSCT, and if so, what type. Here, we discuss these controversies in light of the available literature.
引用
- El Fakih R, Jabbour E, Ravandi F, et al. Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. Am J Hematol. 2017. PMID: 28971501. doi:10.1002/ajh.24926
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。